Should you have any questions, please contact Gerald Hsu, Ph.D., Senior Scientific Liaison, ( or

Transcription

1 Montlukast Sodium Oral Granuls Typ of Posting Rvision Bulltin Posting Dat 29 Sp 2017 Official Dat 01 Oct 2017 Exprt Committ Chmical Mdicins Monographs 5 Rason for Rvision Complianc In accordanc with th Ruls and Procdurs of th Council of Exprts, th Chmical Mdicins Monographs 5 Exprt Committ has rvisd th Montlukast Sodium Oral Granuls Th purpos for th rvision is to: Rvis th accptanc critria of Sulfoxid from NMT 08% to NMT 10% and Total impuritis from NMT 10% to NMT 15% in th Organic Impuritis sction to match th spcification for an FDA approvd drug product Add Dis Tst 4 to accommodat a drug product which was approvd with diffrnt dis tst conditions and accptanc critria than th xisting dis tsts Th liquid chromatographic procdur usd for th analysis of th standard and sampl s in Dis Tst 4 is basd on analyss prformd with th ZORBAX Eclips XDB brand of L1 column manufacturd by Agilnt Th typical rtntion tim for montlukast is about 4 min Th Montlukast Sodium Oral Granuls Rvision Bulltin suprsds th currntly official monograph Th Rvision Bulltin will b incorporatd in th First Supplmnt to USP 41 NF 35 Should you hav any qustions, plas contact Grald Hsu, PhD, Snior Scintific Liaison, ( or gdh@usporg) C186436, C M4631-CHM52015, Rv

2 sulting Rvision Bulltin Official Octobr 1, 2017 Montlukast 1 through a suitabl filtr of 045-µm Montlukast Sodium Oral Granuls por siz or cntrifug to obtain a clar (S Chromatography 621, Systm Suitability) DEFINITION Montlukast Sodium Oral Granuls contain Montlukast So- Dtctor: UV 255 nm dium quivalnt to NLT 900% and NMT 1080% of th Columns labld amount of montlukast (C 35H 36ClNO 3S) Guard: 30-mm 4-mm; packing L11 [NOTE Avoid xposur of sampls containing montlukast Analytical: 46-mm 10-cm; 3-µm packing L11 to light] Column tmpratur: 50 IDENTIFICATION Flow rat: 15 ml/min A ULTRAVIOLET ABSORPTION 197U Injction volum: 20 µl Dilunt: Mthanol and watr (3:1) Run tim: 2 tims th rtntion tim of montlukast Standard : 33 µg/ml of USP Montlukast Di- cyclohxylamin RS in Dilunt Sampls: Standard,, Sampl stock : Nominally 002 mg/ml of and Snsitivity montlukast prpard as follows Transfr th contnts [NOTE Th rlativ rtntion tims for th cis-isomr of on packt to a suitabl volumtric flask, add 66% and montlukast ar about 092 and 10, of th flask volum of Dilunt, shak wll, and sonicat rspctivly] for 15 min with occasional shaking Cool to room tm- pratur, dilut with Dilunt to volum, and mix wll R: NLT 15 btwn th cis-isomr and Sampl : Nominally 2 µg/ml of montlukast montlukast, in Dilunt from th Sampl stock Pass a portion Rlativ standard dviation: NMT 20% for fiv in- of th rsulting through a suitabl filtr of jctions, Standard 045-µm por siz or cntrifug to obtain a clar Signal-to-nois ratio: NLT 10, Snsitivity Wavlngth rang: nm Accptanc critria: Th Sampl xhibits maxmontlukast (C 35H 36ClNO 3S) in th portion of Oral ima only at th sam wavlngths as th Standard Granuls takn: B Th rtntion tim of th major pak of th Sampl corrsponds to that of th Standard, as Rsult = (r U/r S) (C S/C U) (M r1/m r2) 100 obtaind in th Assay r U = pak rspons from th Sampl ASSAY r S = pak rspons from th Standard PROCEDURE C S = concntration of USP Montlukast Dilunt: Mthanol and watr (3:1) Solution A: 02% (v/v) trifluoroactic acid in watr Solution B: Mthanol and actonitril (3:2) C U = nominal concntration of montlukast in th Mobil phas: S Tabl 1 Sampl M r1 = molcular wight of montlukast, Tabl 1 M r2 = molcular wight of montlukast dicyclohxylamin, Tim Solution A Solution B Accptanc critria: 900% 1080% (min) (%) (%) PERFORMANCE TESTS Chang to rad: DISSOLUTION Tst Mdium: 05% (w/v) sodium dodcyl sulfat in watr; 900 ml Do not darat Standard : 033 mg/ml of USP Montlukast Tim: 15 min Dicyclohxylamin RS in Dilunt Solution A: 02% (v/v) trifluoroactic acid in watr : Transfr 10 ml of th Solution B: 02% (v/v) trifluoroactic acid in Standard to a clar 10-mL volumtric flask, add actonitril 4 µl of hydrogn proxid, and mix wll Expos th Mobil phas: Solution A and Solution B (1:1) flask for at last 4 h to ambint light or 10 min to a Standard stock : 033 mg/ml of USP 4 klx cool whit light [NOTE Montlukast is partially Montlukast Dicyclohxylamin RS in mthanol convrtd to th cis-isomr undr ths conditions] (quivalnt to 025 mg/ml of montlukast) Snsitivity : 033 µg/ml of USP Montlukast Standard : (L/900) mg/ml of montlukast in Dicyclohxylamin RS in Dilunt from th Standard Mdium from th Standard stock, whr L is th labl claim in mg/packt of montlukast Sampl : Nominally 024 mg/ml of Sampl : Plac th ntir contnts of on montlukast prpard as follows Transfr th quiva- packt in th baskt At th appropriat tim point, lnt of 60 mg of montlukast from th contnts of th pass a portion of th undr tst through a packts (NLT 15) to a 500-mL volumtric flask, and suitabl filtr to obtain a clar Discard th add 250 ml of Dilunt Shak wll and sonicat for 30 first 10 ml of th filtrat min, with occasional shaking Pass a portion of th r Th Unitd Stats Pharmacopial Convntion All Rights Rsrvd C186436, C M4631-CHM52015, Rv

3 2 Montlukast Official Octobr 1, 2017 (S Chromatography 621, Systm Suitability) Sampl: Standard Dtctor: UV 389 nm Rlativ standard dviation: NMT 20% Column: 30-mm 10-cm; 5-µm packing L11 Column tmpratur: 50 Flow rat: 09 ml/min Injction volum: 25 µl montlukast (C 35H 36ClNO 3S) dissolvd: Run tim: 15 tims th rtntion tim of montlukast Rsult = (r U/r S) C S V (1/L) 100 Sampl: Standard r U = pak rspons from th Sampl r S = pak rspons from th Standard Tailing factor: NMT 15 C S = concntration of montlukast in th Standard Rlativ standard dviation: NMT 20% V = volum of Mdium, 900 ml L = labl claim (mg/packt) Tolrancs: NLT 80% (Q) of th labld amount of montlukast (C 35H 36ClNO 3S) dissolvd: montlukast (C 35H 36ClNO 3S) is dissolvd Tst 3: If th product complis with this tst, th Rsult = (r U/r S) C S V (1/L) 100 labling indicats that it mts USP Dis Tst 3 Mdium: 05% (w/v) sodium dodcyl sulfat in r U = pak rspons of montlukast from th Sampl watr; 900 ml Apparatus 2: 50 rpm r S = pak rspons of montlukast from th Tim: 10 min Standard Solution A: 272 g/l of monobasic potassium phos- C S = concntration of montlukast in th Standard phat in watr Mobil phas: Actonitril and Solution A (70:30) V = volum of Mdium, 900 ml Dilunt: Actonitril and watr (50:50) L = labl claim (mg/packt) : Expos a portion of Stan- Tolrancs: NLT 85% (Q) of th labld amount of dard in a clar glass vial to dirct room light montlukast (C 35H 36ClNO 3S) is dissolvd for about 30 min Tst 2: If th product complis with this tst, th labl- Standard stock : 0524 mg/ml of USP ing indicats that it mts USP Dis Tst 2 Montlukast Dicyclohxylamin RS in Dilunt (quiva- Mdium: 05% (w/v) sodium dodcyl sulfat in lnt to 04 mg/ml of montlukast) watr; 900 ml Standard : mg/ml of USP Montlukast Dicyclohxylamin RS in Mdium from Tim: 15 min th Standard stock (quivalnt to 0005 mg/ Solution A: 007 g/l of monobasic sodium phosphat ml of montlukast) Solution B: Actonitril Sampl : Transfr th ntir contnts of on Mobil phas: Solution A and Solution B (45:55) Add packt to th dis vssl At th spcifid tim 133 ml/l of trithylamin and adjust with phos- point, withdraw 10 ml of sampl from th dis phoric acid to a ph of 67 vssl Pass a portion of th undr tst Standard stock : 01 mg/ml of montlukast through a suitabl filtr Discard th first 5 ml of th from montlukast sodium hydrat prpard as fol- filtrat lows Transfr a suitabl amount of montlukast so- dium hydrat to an appropriat volumtric flask Dis- (S Chromatography 621, Systm Suitability) solv in 4% of th flask volum of mthanol and dilut with Mdium to volum Dtrmin th watr Dtctor: UV 281 nm contnt of montlukast sodium hydrat at th tim of Column: 46-mm 3-cm; 3-µm packing L1 us Column tmpratur: 40 Standard : 0004 mg/ml of montlukast in Flow rat: 08 ml/min Mdium from th Standard stock Injction volum: 25 µl Sampl : Plac th ntir contnts of on Run tim: About 15 tims th rtntion tim of packt in th baskt At th appropriat tim point, montlukast cntrifug a portion of th undr tst Sampls: and Standard (S Chromatography 621, Systm Suitability) [NOTE Th rlativ rtntion tims for Z-isomr and Dtctor: UV 225 nm montlukast ar 08 and 10, rspctivly] Column: 46-mm 5-cm; 18-µm packing L1 Column tmpratur: 35 R: NLT 20 btwn th Z-isomr and Flow rat: 1 ml/min montlukast, Injction volum: 100 µl Tailing factor: NMT 20 for montlukast, Systm Run tim: 15 tims th rtntion tim of suitability montlukast Rlativ standard dviation: NMT 20%, Standard 2017 Th Unitd Stats Pharmacopial Convntion All Rights Rsrvd C186436, C M4631-CHM52015, Rv

4 Official Octobr 1, 2017 Montlukast 3 UNIFORMITY OF DOSAGE UNITS 905 Procdur for contnt uniformity Solution A, Solution B, Mobil phas, and Systm montlukast (C 35H 36ClNO 3S) dissolvd: suitability: Procd as dirctd in Dis Tst 1 Standard : 264 µg/ml of USP Montlukast Rsult = (r U/r S) C S V (1/L) (M r1/m r2) 100 Dicyclohxylamin RS in mthanol Sampl : Nominally 002 mg/ml of r U = pak rspons from th Sampl montlukast prpard as follows Transfr th contnts r S = pak rspons from th Standard of on packt to a suitabl volumtric flask, add 66% C S = concntration of USP Montlukast of th flask volum of mthanol, shak wll, and soni- cat for 15 min with occasional shaking Cool to room tmpratur, dilut with mthanol to volum, V = volum of Mdium, 900 ml and mix wll Pass a portion of th rsulting L = labl claim (mg/packt) through a suitabl filtr of 045-µm por siz or cn- M r1 = molcular wight of montlukast, trifug to obtain a clar M r2 = molcular wight of montlukast : Procd as dirctd in Disdicyclohxylamin, Tst 1, xcpt us an Injction volum of 5 µl Tolrancs: NLT 80% (Q) of th labld amount of montlukast (C 35H 36ClNO 3S) is dissolvd (RB 1-Oct-2016) Tst 4: If th product complis with this tst, th labling indicats that it mts USP Dis Tst 4 montlukast (C 35H 36ClNO 3S) in th packt takn: Mdium: 05% (w/v) sodium dodcyl sulfat in watr; 900 ml Rsult = (r U/r S) (C S/C U) (M r1/m r2) 100 Tim: 20 min r U = pak rspons from th Sampl Solution A: 39 g/l of sodium phosphat monobasic r S = pak rspons from th Standard dihydrat in watr Adjust with dilut phosphoric acid C S = concntration of USP Montlukast to a ph of 37 Mobil phas: Actonitril and Solution A (80:20) Dilunt: Mdium C U = nominal concntration of montlukast in th Standard : 0005 mg/ml of montlukast in Sampl Dilunt from montlukast sodium hydrat Dtrmin M r1 = molcular wight of montlukast, th watr contnt of montlukast sodium hydrat at M r2 = molcular wight of montlukast th tim of us dicyclohxylamin, Sampl : Plac th ntir contnts of on Accptanc critria: Mt th rquirmnts packt in th baskt At th spcifid tim point, withdraw 10 ml of sampl from th dis vssl IMPURITIES Pass a portion of th undr tst through a suitabl filtr papr Discard th first 3 ml of th filtrat Chang to rad: ORGANIC IMPURITIES (S Chromatography 621, Systm Suitability) Dilunt, Solution A, Solution B, Mobil phas, Stan- dard,, Snsitivity Dtctor: UV 254 nm, Sampl,, Column: 46-mm 15-cm; 5-µm packing L1 and : Procd as dirctd in th Tmpraturs Assay Autosamplr: 20 Column: 28 Flow rat: 15 ml/min Calculat th prcntag of any individual dgradation Injction volum: 50 µl product in th portion of Oral Granuls takn: Run tim: NLT 15 tims th rtntion tim of montlukast Rsult = (r U/r S) (C S/C U) (M r1/m r2) (1/F) 100 Sampl: Standard r U = pak rspons of any individual dgradation product from th Sampl Tailing factor: NMT 20 for montlukast r S = pak rspons of montlukast from th Rlativ standard dviation: NMT 20% Standard C S = concntration of USP Montlukast montlukast (C 35H 36ClNO 3S) dissolvd: C U = nominal concntration of montlukast in th Rsult = (r U/r S) C S V (1/L) 100 M r1 Sampl = molcular wight of montlukast, M r2 = molcular wight of montlukast r U = pak rspons from th Sampl dicyclohxylamin, r S = pak rspons from th Standard F = rlativ rspons factor (s Tabl 2) C S = concntration of montlukast in th Standard Accptanc critria: S Tabl 2 Disrgard any pak with an ara lss than that of th Snsitivity V = volum of Mdium, 900 ml L = labl claim (mg/packt) Tolrancs: NLT 80% (Q) of th labld amount of montlukast (C 35H 36ClNO 3S) is dissolvd (RB 1-Oct-2017) 2017 Th Unitd Stats Pharmacopial Convntion All Rights Rsrvd C186436, C M4631-CHM52015, Rv

5 4 Montlukast Official Octobr 1, 2017 Tabl 2 Rlativ Rlativ Accptanc Rtntion Rspons Critria, Nam Tim Factor NMT (%) 10 (RB 1-Oct- Sulfoxid b a, ) Montlukast kton c cis-isomr d Montlukast 10 Mthylkton f, 104 Michal adduct 1 g, 116 Michal adduct 2 h, 118 Mthylstyrn i, 155 Any othr individual dgradation product (RB 1-Oct- Total impuritis 2017) a Ths two impuritis ar not rsolvd by th mthod and nd to b intgratd togthr to dtrmin conformanc b [1-[[[1-[3-[(E)-2-(7-Chloroquinolin-2-yl)thnyl]phnyl]-3-[2-(1-hydroxy- 1-mthylthyl)phnyl]propyl]sulfinyl]mthyl]cyclopropyl]actic acid c (E)-1-{3-[2-(7-Chloroquinolin-2-yl)vinyl]phnyl}-3-[2-(2-hydroxypropan-2- yl)phnyl]propan-1-on d [1-[[[(1R)-1-[3-[(Z)-2-(7-Chloroquinolin-2-yl)thnyl]phnyl]-3-[2-(1-hydroxy-1-mthylthyl)phnyl]propyl]sulfanyl]mthyl]cyclopropyl]actic acid This is a procss and is includd in th tabl for idntification only This is controlld in th drug substanc It is not to b rportd for th drug product and should not b includd in th total impuritis f [1-[[[(1R)-3-(2-Actylphnyl)-1-[3-[(E)-2-(7-chloroquinolin-2- yl)thnyl]phnyl]propyl]sulfanyl]mthyl]cyclopropyl]actic acid g (1-{[(R)-1-(3-[(R)-1-{[1-(Carboxymthyl)cyclopropyl]mthylthio}-2-(7- chloroquinolin-2-yl)thyl]phnyl)-3-[2-(2-hydroxypropan-2-yl)phnyl- ]propylthio]mthyl}cyclopropyl)actic acid h (1-{[(R)-1-(3-[(S)-1-{[1-(Carboxymthyl)cyclopropyl]mthylthio}-2-(7- chloroquinolin-2-yl)thyl]phnyl)-3-[2-(2-hydroxypropan-2-yl)phnyl- ]propylthio]mthyl}cyclopropyl)actic acid i [1-[[[(1R)-1-[3-[(E)-2-(7-Chloroquinolin-2-yl)thnyl]phnyl]-3-[2-(1- mthylthnyl)phnyl]propyl]sulfanyl]mthyl]cyclopropyl]actic acid ADDITIONAL REQUIREMENTS PACKAGING AND STORAGE: Prsrv in tight containrs, protctd from light Stor at controlld room tmpratur LABELING: Whn mor than on Dis tst is givn, th labling stats th tst usd only if Tst 1 is not usd USP REFERENCE STANDARDS 11 USP Montlukast Dicyclohxylamin RS C 35H 36ClNO 3S C 12H 23N Th Unitd Stats Pharmacopial Convntion All Rights Rsrvd C186436, C M4631-CHM52015, Rv